Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma

被引：36
|
作者：
Hill, Brian T. [1 ]
Roberts, Zachary J. [2 ]
Xue, Allen [2 ]
Rossi, John M. [2 ]
Smith, Mitchell R. [1 ,3 ]
机构：
[1] Cleveland Clin Fdn, Taussig Canc Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Kite, Santa Monica, CA USA
[3] George Washington Canc Ctr, Washington, DC USA
来源：
BONE MARROW TRANSPLANTATION | 2020年 / 55卷 / 06期
关键词：
D O I：
10.1038/s41409-019-0657-3
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：1184 / 1187
页数：4
相关论文
共 50 条
  • [1] Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma
    Brian T. Hill
    Zachary J. Roberts
    Allen Xue
    John M. Rossi
    Mitchell R. Smith
    Bone Marrow Transplantation, 2020, 55 : 1184 - 1187
  • [2] Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study
    Tun, Aung M.
    Patel, Romil D.
    St-Pierre, Frederique
    Ouchveridze, Evguenia
    Niu, Alex
    Thordardottir, Thorunn
    Obasi, Jennifer
    Rosenthal, Allison
    Pophali, Priyanka A.
    Fenske, Timothy S.
    Karmali, Reem
    Ahmed, Sairah
    Johnston, Patrick B.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (09) : 1712 - 1720
  • [3] Liquid biopsy for disease monitoring after anti-CD19 chimeric antigen receptor T cell in diffuse large B-cell lymphoma
    Maluquer, Clara
    Bellosillo, Beatriz
    Mussetti, Alberto
    Domingo-Domenech, Eva
    Parody, Rocio
    Fernandez-Ibarrondo, Lierni
    Velasco, Roser
    Moreno-Gonzalez, Gabriel
    Sanz, Gabriela
    Cortes, Montserrat
    Sureda, Anna
    EJHAEM, 2021, 2 (01): : 112 - 114
  • [4] Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy
    Hill, Brian T.
    Roth, Caroline J.
    Kositsky, Rachel
    Dave, Tushar
    Love, Cassandra
    McKinney, Matthew
    Galal, Ahmed
    Neff, Jadee L.
    Mian, Agrima
    Kendall, Ellen
    Ondrejka, Sarah L.
    Chiaramonte, Matthew
    Bhagat, Govind
    Ofori, Kenneth
    Reshef, Ran
    Kovach, Alexandra E.
    Sethi, Tarsheen
    Mason, Emily F.
    Bhaskar, Shakthi
    Oluwole, Olalekan O.
    Pallas, Christopher
    Ghosh, Nilanjan
    Ferdman, Robert
    Chen, George L.
    Hernandez-Ilizaliturri, Francisco J.
    Zurko, Joanna C.
    Cunningham, Ashley
    Shah, Nirav N.
    Hu, Boyu
    Stephens, Deborah M.
    Ghosh, Monalisa
    Bailey, Neil
    Patel, Krish
    Pagel, John M.
    Kannan, Kavya Kannamma
    Hsi, Eric D.
    Vaidya, Rakhee
    Ip, Andrew
    Goy, Andre H.
    Kambhampati, Swetha
    Ohgami, Robert S.
    Andreadis, Charalambos
    Thacker, Elizabeth
    Rozzi, Chrissie
    Parker, Clay
    Happ, Lanie
    Dave, Sandeep S.
    BLOOD, 2021, 138
  • [5] Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy
    Zixun Yan
    Li Li
    Di Fu
    Wen Wu
    Niu Qiao
    Yaohui Huang
    Lu Jiang
    Depei Wu
    Yu Hu
    Huilai Zhang
    Pengpeng Xu
    Shu Cheng
    Li Wang
    Sahin Lacin
    Muharrem Muftuoglu
    Weili Zhao
    Frontiers of Medicine, 2023, 17 : 699 - 713
  • [6] Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy
    Zixun Yan
    Li Li
    Di Fu
    Wen Wu
    Niu Qiao
    Yaohui Huang
    Lu Jiang
    Depei Wu
    Yu Hu
    Huilai Zhang
    Pengpeng Xu
    Shu Cheng
    Li Wang
    Sahin Lacin
    Muharrem Muftuoglu
    Weili Zhao
    Frontiers of Medicine, 2023, 17 (04) : 699 - 713
  • [7] Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy
    Yan, Zixun
    Li, Li
    Fu, Di
    Wu, Wen
    Qiao, Niu
    Huang, Yaohui
    Jiang, Lu
    Wu, Depei
    Hu, Yu
    Zhang, Huilai
    Xu, Pengpeng
    Cheng, Shu
    Wang, Li
    Lacin, Sahin
    Muftuoglu, Muharrem
    Zhao, Weili
    FRONTIERS OF MEDICINE, 2023, 17 (04) : 699 - 713
  • [8] Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma A Review
    Locke, Frederick L.
    Go, William Y.
    Neelapu, Sattva S.
    JAMA ONCOLOGY, 2020, 6 (02) : 281 - 290
  • [9] Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist
    Jacobson, Caron A.
    Farooq, Umar
    Ghobadi, Armin
    ONCOLOGIST, 2020, 25 (01): : E138 - E146
  • [10] Anti-CD19 chimeric antigen receptor T-cell therapy for B-cell acute lymphoid leukemia
    Rapoport, Aaron P.
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 1019 - 1020
12345